Citius Pharmaceuticals, Inc.
NASDAQ:CTXR
0.4822 (USD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.194 | 0.18 | 0.165 | 0.152 | 0.001 | 0.002 | 0.003 | 0.001 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.194 | -0.18 | -0.165 | -0.152 | -0.001 | -0.002 | -0.003 | -0.001 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 14.82 | 17.655 | 12.241 | 8.813 | 8.597 | 6.563 | 2.936 | 2.933 | 1.797 | 0.438 | 0.492 | 0.001 | 0 |
| General & Administrative Expenses
| 21.912 | 15.661 | 11.291 | 8.898 | 7.001 | 7.226 | 7.05 | 4.516 | 1.433 | 0.715 | 0.028 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.019 | 0 |
| SG&A
| 21.912 | 15.661 | 11.291 | 8.898 | 7.001 | 7.226 | 7.05 | 4.516 | 1.433 | 0.715 | 0.028 | 0.02 | 0.026 |
| Other Expenses
| 3.586 | 1.455 | 0.06 | 0.11 | 0.716 | 1.268 | 0.732 | 0.732 | 0.486 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 36.732 | 33.316 | 23.532 | 17.711 | 15.598 | 13.789 | 9.986 | 7.449 | 3.23 | 1.144 | 0.028 | 0.02 | 0.026 |
| Operating Income
| -36.732 | -33.316 | -23.532 | -17.711 | -15.598 | -13.789 | -9.986 | -7.449 | -3.23 | -1.153 | -0.028 | -0.02 | -0.026 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.586 | 0.251 | 0.477 | 0.163 | 0.036 | 1.268 | 0.452 | -0.838 | 0.332 | -0.119 | -0.003 | -0.002 | -0.001 |
| Income Before Tax
| -31.967 | -33.065 | -23.054 | -17.548 | -15.562 | -12.537 | -10.385 | -8.296 | -2.902 | -1.272 | -0.031 | -0.022 | -0.026 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.576 | 0.576 | 0.071 | 0.126 | 0.016 | 1.284 | 0.851 | 0.009 | 0.004 | -0.119 | -1.183 | -0.001 | 0 |
| Net Income
| -32.543 | -33.641 | -23.125 | -17.674 | -15.579 | -12.537 | -10.385 | -8.296 | -2.902 | -1.272 | -0.031 | -0.022 | -0.026 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.22 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0 | -0.042 | -0.029 | -0.035 |
| EPS Diluted
| -0.22 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0 | -0.042 | -0.029 | -0.035 |
| EBITDA
| -36.538 | -32.885 | -23.045 | -17.38 | -15.545 | -12.519 | -9.984 | -7.447 | -3.227 | -0.119 | -0.028 | -0.02 | -0.025 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |